My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista de Osteoporosis y Metabolismo Mineral
On-line version ISSN 2173-2345Print version ISSN 1889-836X
Abstract
GIFRE, L et al. Effect of treatment with denosumab for 24 months in individuals with recent spinal cord injury with osteoporosis. Rev Osteoporos Metab Miner [online]. 2022, vol.14, n.2, pp.88-92. Epub Sep 12, 2022. ISSN 2173-2345. https://dx.doi.org/10.4321/s1889-836x2022000200005.
Introduction:
Osteoporosis development is a frequent complication associated with spinal cord injury (SCI), especially at the sublesional level. However, at present, data on its treatment are scarce.
Aim:
To analyze bone mineral density (BMD) and bone turnover markers (BTM) after 2-year treatment with denosumab in individuals with SCI-related osteoporosis.
Methods:
Prospective study including patients with recent SCI and related osteoporosis treated with denosumab for 24 months. In all patients, BTMs (bone ALP, sCTX and PINP), 25-OH-vitamin D levels and lumbar and femoral BMD were assessed at baseline and at 12 and 24 months.
Results:
13 patients (aged 39±15 years) with recent SCI (mean duration of 15 months) and osteoporosis treated with denosumab for 24 months were included. Patients showed a significant increase in BMD at lumbar spine and proximal femur after 12 months of treatment with denosumab, with a further increase in BMD at 24 months of follow-up, reaching an increase of 9.1% in lumbar spine, 4.4% in femoral neck and 5.3% total femur, respectively. BTM significantly decrease at 12 months and remained decreased at 24 months of follow-up. No skeletal fractures or treatment-related adverse events were observed during follow-up.
Conclusions:
Treatment with denosumab during 24 months increases lumbar and femoral BMD and decreases BTMs in patients with recent SCI. Denosumab may be a promising therapeutic option in SCI-related osteoporosis.
Keywords : denosumab; osteoporosis; spinal cord injury; bone mineral density; bone turnover markers.